Marc Damelin
Mersana Therapeutics (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research, Synthesis and Biological Evaluation, Radiopharmaceutical Chemistry and Applications, Cancer Cells and Metastasis
Most-Cited Works
- → Tumour-initiating cells: challenges and opportunities for anticancer drug discovery(2009)841 cited
- → Hyperconserved CpG domains underlie Polycomb-binding sites(2007)175 cited
- → A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions(2017)154 cited
- → Evolving Strategies for Target Selection for Antibody-Drug Conjugates(2015)149 cited
- → The Genome-Wide Localization of Rsc9, a Component of the RSC Chromatin-Remodeling Complex, Changes in Response to Stress(2002)145 cited
- → Mapping Interactions between Nuclear Transport Factors in Living Cells Reveals Pathways through the Nuclear Pore Complex(2000)138 cited
- → Interactions between a Nuclear Transporter and a Subset of Nuclear Pore Complex Proteins Depend on Ran GTPase(1999)130 cited
- → Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions(2015)87 cited
- → Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells(2011)79 cited
- → Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells(2012)78 cited